Amphastar Pharmaceuticals, Inc. (AMPH) said the FDA has approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid. The company plans to launch Glucagon for Injection Emergency Kit, which it previously referred to as AMP-001, within two months.

Create Account

Dark

chart

exchange

Check out our Level2View

Amphastar Pharmaceuticals, Inc. (AMPH) said the FDA has approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid. The company plans to launch Glucagon for Injection Emergency Kit, which it previously referred to as AMP-001, within two months.

RTTNews | Dec 29, 2020 06:12AM EST

06:11 Tuesday, December 29, 2020 (RTTNews.com) - Amphastar Pharmaceuticals, Inc. (AMPH) said the FDA has approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid. The company plans to launch Glucagon for Injection Emergency Kit, which it previously referred to as AMP-001, within two months.

Amphastar's CEO, Jack Zhang, stated: "This approval is yet another milestone for the Company and marks the first-ever FDA approval of a generic version of rDNA Glucagon."

Read the original article on RTTNews ( https://www.rttnews.com/3156512/amphastar-pharma-fda-approves-glucagon-for-injection-emergency-kit-1-mg-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved